Malaysian Reinsurance Berhad (Malaysian Re) and China Reinsurance Life Insurance Company Limited (China Re Life) have signed a landmark reinsurance treaty to establish Malaysia’s first dedicated framework for Cancer Precision Medicine (CPM) treatment coverage. This agreement, formalised on 18 June 2026, aims to enhance access to advanced cancer treatments, including CAR-T cell therapy and targeted therapies, as well as overseas oncology treatment.
The treaty was signed during a visit by Li Qi, General Manager of China Re Life, to Malaysian Re’s headquarters in Kuala Lumpur. This collaboration, in development since 2025, marks a significant step in providing comprehensive cancer care solutions in Malaysia. The initiative is part of a broader healthcare ecosystem developed by Malaysian Re, which includes partnerships with hospitals and pharmaceutical companies to ensure accessible and affordable cancer care.
Ahmad Noor Azhari Abdul Manaf, President and CEO of Malaysian Re, highlighted the importance of the treaty, stating, “With more than 60% of cancer patients diagnosed at late stages, this treaty with China Re Life represents an important milestone in expanding access to advanced cancer treatments with better treatment outcomes for Malaysians.”
Li Qi of China Re Life added, “Our collaboration with Malaysian Re in Cancer Precision Medicine is a natural expression of our commitment to addressing complex, underserved risk categories that matter deeply to people’s lives.”
The treaty also includes an overseas treatment benefit, allowing patients to seek treatment at designated oncology centres in China. Moving forward, Malaysian Re and China Re Life plan to explore further collaborations in critical illness, longevity, and health management solutions across Southeast Asia.
